ABBV stock forecast
Our latest prediction for AbbVie, Inc.'s stock price was made on the Dec. 11, 2018 when the stock price was at 88.17$.
In the short term (2weeks), ABBV's stock price should outperform the market by 0.43%. During that period the price should oscillate between -4.14% and +5.05%.
In the medium term (3months), ABBV's stock price should outperform the market by 1.02%. During that period the price should oscillate between -8.29% and +12.80%.Get email alerts
Create a solid portfolio with ABBV
About AbbVie, Inc.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
At the moment the company generates 34057M USD in revenues.
On its last earning announcement, the company reported a profit of 5.65$ per share.
The book value per share is -1.94$
Three months stock forecastDec. 11, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|